Loading…
Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.
Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.
Makes active ingredients and finished tablets or capsules to the customer's specification under supply agreements, so it sells manufacturing capacity and know-how, not drugs under its own name. Once a product is transferred, orders tend to continue for as long as the drug sells. Sites span Europe, the US and China.
In one line: A Swiss Lonza / Catalent.
Moat: narrow (regulatory licence, customer qualification, scale). FDA/EMA-approved manufacturing sites are costly and slow to requalify or replace.
Headquarters: Zofingen, Switzerland · Founded: 1873 · Employees: 3,891
Size Siegfried (SFZN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $3.98B, the 65th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 72.00 on 6 Nov 2026.
Performance Over six months the shares fell 10.2%, against +4.0% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 3.6% over the last twelve months (peer median +7.9%); the operating margin is 15.7% (peer median 17.8%).
Valuation It trades at 17.8× forward earnings against a peer median of 21.8× (8th cheapest of 17).
Capital Return on invested capital runs 4.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 1.34B | CHF 1.33B | CHF 1.29B | CHF 1.27B | CHF 1.23B |
| Revenue growth | — | +3% | +2% | +3% | — |
| Gross profit | CHF 362M | CHF 352M | CHF 329M | CHF 320M | CHF 319M |
| EBITDA | CHF 313M | CHF 307M | CHF 277M | CHF 249M | CHF 310M |
| Net income | CHF 171M | CHF 169M | CHF 160M | CHF 113M | CHF 156M |
| Free cash flow | -CHF 18.2M | CHF 9.97M | -CHF 5.24M | CHF 72.2M | CHF 30.9M |
| Capital expenditure | CHF 201M | CHF 231M | CHF 181M | CHF 137M | CHF 115M |
| Total debt | n/a | CHF 575M | CHF 490M | CHF 525M | CHF 590M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| WuXi AppTec 603259.SS | $67.0B | +34% | +32% | 43% | 18.1× | 7.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | $8.07B | +23% | +18% | 17% | 41.4× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.37B | +30% | +9% | 3% | 159.9× | n/a |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SFZN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.5% | +5.8% | 10th highest of 21 |
| 6-month return | -10.2% | +4.0% | 5th lowest of 21 |
| Distance from 52-week high | -29.1% | -22.0% | 7th lowest of 21 |
| Revenue growth (TTM) | +3.6% | +7.9% | 9th lowest of 20 |
| Operating margin | 15.7% | 17.8% | 9th lowest of 18 |
| Forward P/E | 17.8× | 21.8× | 8th cheapest of 17 |
| ROIC minus cost of capital | +4.3 pp | +7.6 pp | 7th lowest of 18 |
| EV / EBITDA | 13.0× | 18.8× | 5th cheapest of 10 |
| Net debt / EBITDA | 2.6× | -0.5× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | n/a | n/a | n/a |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |